RTI-121 is an investigational drug that has been studied as a potential treatment for certain neurological disorders, particularly related to cognitive impairment and related conditions. It acts as a selective modulator of the mGluR2 receptor, which is part of the metabotropic glutamate receptor family. Research into RTI-121 has primarily focused on its effects in the context of treating conditions like schizophrenia and other disorders characterized by cognitive deficits.
Articles by others on the same topic
There are currently no matching articles.